Why Has RBC Capital Markets Given Dechra Pharmaceuticals (LON:DPH) a GBX 1080 Price Target
Research professionals at RBC Capital Markets began issuing coverage on shares of Dechra Pharmaceuticals (LON:DPH) in analysts note issued to clients on 15 December. The firm set Sector Perform rating on the stock. RBC Capital Markets’s target price of GBX 1080 suggests potential of 8.00% from the stock’s last price.
From a total of 7 analysts covering Dechra Pharmaceuticals PLC (LON:DPH) stock, 4 rate it a ”Buy”, 0 a “Sell”, and 5 a ”Hold”. This means that 44% of the ratings are positive. The highest target price is GBX 1141 while the lowest target price is GBX 970. The mean of all analyst targets is GBX 1060.86 with a 6.82% above today’s (GBX 1001.4) stock price. Dechra Pharmaceuticals PLC was the topic of 20 analyst reports since August 3, 2015 according to the firm StockzIntelligence Inc. FinnCap maintained shares on November 17 with “Hold” rating. Investec maintained shares with “Buy” rating and GBX 1141 target share price in a report from an October 23. Panmure Gordon maintained DPH stock in a recent report from October 23 with “Buy” rating. Jefferies maintained the rating on September 10. Jefferies has a “Buy” rating and a GBX 1140 price target on shares. Finally, N+1 Singer maintained the stock with “Hold” rating in a report issued on an October 23.
Approximately 2,271 shares of stock traded hands. Dechra Pharmaceuticals plc (LON:DPH) has declined 5.13% since May 18, 2015 and is downtrending. It has underperformed by 1.45% the S&P500.
Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The company has a market cap of 881.55 million GBP. The Firm is engaged in the development, manufacture and marketing of products for veterinarians across the world. It has 45.53 P/E ratio. The Company’s divisions include European Pharmaceuticals, consists of Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing; North American Pharmaceuticals, consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, and Pharmaceuticals Research and Development.